Guidance on the use of docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer
National Institute for Clinical Excellence
Record ID 32002000344
To provide guidance on the use of docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer.
Authors' recomendations: Guidance 1.1 Chemotherapy for non-small cell lung cancer (NSCLC) should be considered as an option in patients who are unsuitable for, or considered unlikely to respond to an attempt at curative treatment. 1.2 Gemcitabine, paclitaxel, and vinorelbine should each be considered as part of first-line chemotherapy options for advanced (stage III and IV) NSCLC patients. Combination of these three agents individually with platinum-based chemotherapy, where tolerated, is likely to be the most effective approach. 1.3 Docetaxel monotherapy should be considered where second line treatment is appropriate for patients with locally advanced or metastatic NSCLC when relapse has occurred after prior chemotherapy. 1.4 Chemotherapy regimens should be administered under the supervision of appropriately trained health professionals experienced in the use of cancer chemotherapeutic agents and should be accompanied by best supportive care. Informed decisions regarding appropriate chemotherapy should take account of side effect profiles, use of concurrent radiotherapy, performance status of the individual being treated and patient and carer preferences. Total cost differences between the various chemotherapy regimens should also be taken into account.
Authors' methods: Systematic review
Project Status: Completed
URL for project: http://www.nice.org.uk/cat.asp?c=17338
Year Published: 2001
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
- Drug Therapy
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Organisation Name: National Institute for Clinical Excellence
Contact Address: MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: National Institute for Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.